Loading…
Indian listed arm of P&G's Gillette, selling razors, blades and other male grooming products.
Indian listed arm of P&G's Gillette, selling razors, blades and other male grooming products.
Sells brands owned by Procter & Gamble, so it pays royalties and technology fees to the parent and buys some goods from group companies, while P&G holds the majority of its shares. Reaches shoppers through distributors to general stores and modern retail chains.
Moat: narrow (brand, IP / patents, distribution). Global Gillette brand and blade-technology patents support premium pricing versus local razors.
Headquarters: Mumbai, India · Founded: 1984 · Employees: 1,098
Size Gillette India (GILLETTE.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $2.56B, the 319th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹7,406 on 6 Nov 2026.
Performance Over six months the shares fell 6.6%, against -3.3% for the median peer and 0.0% for the India market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 8.0% over the last twelve months (peer median +3.0%); the operating margin is 27.9% (peer median 10.1%).
Valuation It trades at 33.0× forward earnings against a peer median of 20.4× (3rd most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 58.9 points above its cost of capital (11.1% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹31.8B | ₹31.0B | ₹29.8B | ₹24.8B | ₹22.6B |
| Revenue growth | — | +4% | +20% | +10% | — |
| Gross profit | ₹16.6B | ₹15.1B | ₹13.5B | ₹9.06B | ₹8.68B |
| EBITDA | ₹9.61B | ₹9.69B | ₹8.23B | ₹5.42B | ₹4.88B |
| Net income | ₹6.68B | ₹6.54B | ₹5.57B | ₹3.56B | ₹2.89B |
| Free cash flow | n/a | ₹5.89B | ₹3.02B | ₹3.96B | ₹3.50B |
| Capital expenditure | n/a | ₹433M | ₹436M | ₹787M | ₹1.16B |
| Total debt | n/a | ₹200,000 | ₹500,000 | ₹500,000 | ₹1.20M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Gillette India GILLETTE.NS | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% |
| Godrej Consumer Products GODREJCP.NS | $9.19B | -18% | +12% | 18% | 37.0× | 31.7% |
| Edgewell Personal Care EPC | $1.29B | +32% | -7% | 6% | 12.4× | 4.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GILLETTE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | +3.1% | 10th lowest of 21 |
| 6-month return | -6.6% | -3.3% | 10th lowest of 21 |
| Distance from 52-week high | -23.4% | -26.9% | 9th highest of 21 |
| Revenue growth (TTM) | +8.0% | +3.0% | 5th highest of 21 |
| Operating margin | 27.9% | 10.1% | 2nd highest of 21 |
| Forward P/E | 33.0× | 20.4× | 3rd most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 16.0% | -0.1% | 4th most demanding of 18 |
| Growth delivered (Del g) | +13.0% | +4.6% | 7th highest of 18 |
| Hurdle (Req g minus delivered) | +2.9 pp | -3.2 pp | 7th most demanding of 18 |
| ROIC minus cost of capital | +58.9 pp | +5.3 pp | 2nd highest of 21 |
| EV / EBITDA | 25.1× | 11.8× | most expensive of 15 |
| Net debt / EBITDA | -0.3× | -0.9× | 6th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gillette India GILLETTE.NS | India | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% | +13.0% |
| LG H&h 051900.KS | South Korea | $2.56B | -8% | -3% | 3% | 18.5× | -0.1% | -4.1% |
| Winner Medical 300888.SZ | China | $2.69B | -2% | +4% | 11% | 20.9× | -4.3% | -2.6% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.40B | -29% | -2% | 24% | 27.3× | 15.4% | +7.4% |
| Giant Biogene 2367.HK | Hong Kong | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% | +34.9% |
| Proya Cosmetics 603605.SS | China | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% | +23.1% |
| Softcare 2698.HK | Hong Kong | $2.20B | -5% | +25% | 25% | 14.4× | 8.7% | +20.9% |
| KOSE 4922.T | Japan | $2.16B | +7% | +3% | 4% | 27.2× | n/a | n/a |
| Cosmax 192820.KS | South Korea | $2.13B | +21% | +16% | 8% | 16.6× | n/a | n/a |
| Lion 4912.T | Japan | $3.19B | +21% | +6% | 8% | 19.9× | -2.4% | +3.5% |
| Hengan Int'l 1044.HK | Hong Kong | $3.28B | -16% | +2% | 11% | 9.1× | -8.8% | -0.1% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.29B | +20% | +4% | 6% | 50.2× | 17.6% | +1.9% |
| Pola Orbis 4927.T | Japan | $1.96B | +8% | +1% | 10% | 28.8× | -3.1% | -0.7% |
| Kolmar Korea 161890.KS | South Korea | $1.89B | +23% | +13% | 10% | 13.0× | -0.9% | +15.5% |
| Blue Moon 6993.HK | Hong Kong | $1.88B | -15% | -2% | -2% | 93.6× | n/a | n/a |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.84B | -28% | +7% | 9% | 21.2× | 4.5% | +15.3% |
| Coty COTY | United States | $3.57B | +64% | -1% | 5% | 13.3× | 11.3% | +4.6% |
| Emami EMAMILTD.NS | India | $1.80B | -15% | +3% | 20% | 21.4× | 21.7% | +5.6% |
| Interparfums ITP.PA | France | $3.65B | +72% | -4% | 18% | 27.5× | 15.9% | +19.6% |
| Shanghai Jahwa United 600315.SS | China | $1.74B | -13% | +9% | 2% | 18.1× | 17.1% | -2.1% |
| Pigeon 7956.T | Japan | $1.66B | +30% | +7% | 13% | 26.3× | -1.3% | +1.9% |